Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 71

1.

The Prevalence of Nodular Regenerative Hyperplasia in Inflammatory Bowel Disease Patients Treated with Thioguanine Is Not Associated with Clinically Significant Liver Disease.

van Asseldonk DP, Jharap B, Verheij J, den Hartog G, Westerveld DB, Becx MC, Russel MG, Engels LG, de Jong DJ, Witte BI, Mulder CJ, van Nieuwkerk CM, Bloemena E, de Boer NK, van Bodegraven AA.

Inflamm Bowel Dis. 2016 Sep;22(9):2112-20. doi: 10.1097/MIB.0000000000000869.

PMID:
27482972
2.

Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.

Wong DR, Coenen MJ, Vermeulen SH, Derijks LJ, van Marrewijk CJ, Klungel OH, Scheffer H, Franke B, Guchelaar HJ, de Jong DJ, Engels LG, Verbeek AL, Hooymans PM; TOPIC recruitment team.

J Crohns Colitis. 2016 Jul 9. pii: jjw130. [Epub ahead of print]

PMID:
27402913
3.

Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.

Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH, te Morsche RH, Newman WG, Scheffer H, Guchelaar HJ, Franke B; TOPIC Recruitment Team.

Gastroenterology. 2015 Oct;149(4):907-17.e7. doi: 10.1053/j.gastro.2015.06.002. Epub 2015 Jun 11.

PMID:
26072396
4.

Impact of surveillance for Barrett's oesophagus on tumour stage and survival of patients with neoplastic progression.

Kastelein F, van Olphen SH, Steyerberg EW, Spaander MC, Bruno MJ; ProBar-Study Group.

Gut. 2016 Apr;65(4):548-54. doi: 10.1136/gutjnl-2014-308802. Epub 2015 Apr 22.

PMID:
25903690
5.

Surveillance in patients with long-segment Barrett's oesophagus: a cost-effectiveness analysis.

Kastelein F, van Olphen S, Steyerberg EW, Sikkema M, Spaander MC, Looman CW, Kuipers EJ, Siersema PD, Bruno MJ, de Bekker-Grob EW; ProBar-study group.

Gut. 2015 Jun;64(6):864-71. doi: 10.1136/gutjnl-2014-307197. Epub 2014 Jul 18.

PMID:
25037191
6.

Vedolizumab as induction and maintenance therapy for Crohn's disease.

Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, Lukas M, Fedorak RN, Lee S, Bressler B, Fox I, Rosario M, Sankoh S, Xu J, Stephens K, Milch C, Parikh A; GEMINI 2 Study Group.

N Engl J Med. 2013 Aug 22;369(8):711-21. doi: 10.1056/NEJMoa1215739.

7.

The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.

Wong DR, Pierik M, Seinen ML, van Bodegraven AA, Gilissen LP, Bus P, Bakker JA, Masclee AA, Neef C, Engels LG, Hooymans PM.

J Crohns Colitis. 2014 Feb;8(2):120-8. doi: 10.1016/j.crohns.2013.07.004. Epub 2013 Aug 7.

PMID:
23932783
8.

[Irritable bowel syndrome: from guideline to made-to-measure care?].

Engels LG.

Ned Tijdschr Geneeskd. 2012;156(21):A4783. Dutch.

PMID:
22617074
9.

Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.

Gilissen LP, Wong DR, Engels LG, Bierau J, Bakker JA, Paulussen AD, Romberg-Camps MJ, Stronkhorst A, Bus P, Bos LP, Hooymans PM, Stockbrügger RW, Neef C, Masclee AA.

J Crohns Colitis. 2012 Jul;6(6):698-707. doi: 10.1016/j.crohns.2011.12.003. Epub 2012 Jan 10.

PMID:
22398098
10.

Red meat intake-induced increases in fecal water genotoxicity correlate with pro-carcinogenic gene expression changes in the human colon.

Hebels DG, Sveje KM, de Kok MC, van Herwijnen MH, Kuhnle GG, Engels LG, Vleugels-Simon CB, Mares WG, Pierik M, Masclee AA, Kleinjans JC, de Kok TM.

Food Chem Toxicol. 2012 Feb;50(2):95-103. doi: 10.1016/j.fct.2011.10.038. Epub 2011 Oct 14.

PMID:
22019696
11.

Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.

Kastelein F, Spaander MC, Biermann K, Steyerberg EW, Kuipers EJ, Bruno MJ; Probar-study Group.

Gastroenterology. 2011 Dec;141(6):2000-8; quiz e13-4. doi: 10.1053/j.gastro.2011.08.036. Epub 2011 Aug 28.

PMID:
21878200
12.

N-nitroso compound exposure-associated transcriptomic profiles are indicative of an increased risk for colorectal cancer.

Hebels DG, Sveje KM, de Kok MC, van Herwijnen MH, Kuhnle GG, Engels LG, Vleugels-Simon CB, Mares WG, Pierik M, Masclee AA, Kleinjans JC, de Kok TM.

Cancer Lett. 2011 Oct 1;309(1):1-10. doi: 10.1016/j.canlet.2011.05.007. Epub 2011 Jun 12.

13.

Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid.

Kuiper EM, Hansen BE, Adang RP, van Nieuwkerk CM, Timmer R, Drenth JP, Spoelstra P, Brouwer HT, Kuyvenhoven JP, van Buuren HR; Dutch PBC Study Group.

Eur J Gastroenterol Hepatol. 2010 Dec;22(12):1495-502. doi: 10.1097/MEG.0b013e32834059e7.

PMID:
21389798
14.

Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case-control study.

Keszthelyi D, Jansen SV, Schouten GA, de Kort S, Scholtes B, Engels LG, Masclee AA.

Aliment Pharmacol Ther. 2010 Nov;32(9):1124-8. doi: 10.1111/j.1365-2036.2010.04453.x. Epub 2010 Sep 13.

15.

Fatigue and health-related quality of life in inflammatory bowel disease: results from a population-based study in the Netherlands: the IBD-South Limburg cohort.

Romberg-Camps MJ, Bol Y, Dagnelie PC, Hesselink-van de Kruijs MA, Kester AD, Engels LG, van Deursen C, Hameeteman WH, Pierik M, Wolters F, Russel MG, Stockbrügger RW.

Inflamm Bowel Dis. 2010 Dec;16(12):2137-47. doi: 10.1002/ibd.21285.

PMID:
20848468
16.

The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis.

Kuiper EM, Hansen BE, Lesterhuis W, Robijn RJ, Thijs JC, Engels LG, Koek GH, Aparicio MN, Kerbert-Dreteler MJ, van Buuren HR; Dutch PBC study group.

Clin Res Hepatol Gastroenterol. 2011 Jan;35(1):29-33. doi: 10.1016/j.gcb.2010.07.018.

PMID:
20810227
17.

Psychometric validation of the Dutch translation of the quality of life in reflux and dyspepsia (QOLRAD) questionnaire in patients with gastroesophageal reflux disease.

Engels LG, Klinkenberg-Knol EC, Carlsson J, Halling K.

Health Qual Life Outcomes. 2010 Aug 17;8:85. doi: 10.1186/1477-7525-8-85.

18.

Safe 6-thioguanine therapy of a TPMT deficient Crohn's disease patient by using therapeutic drug monitoring.

Mares WG, Wong DR, Gilissen LP, Masclee AA, Hooymans PM, Engels LG.

J Crohns Colitis. 2009 Jun;3(2):128-30. doi: 10.1016/j.crohns.2009.02.002. Epub 2009 Mar 16.

PMID:
21172256
19.
20.

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group.

Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.

PMID:
19208346
Items per page

Supplemental Content

Loading ...
Write to the Help Desk